DE 30.6.2023
Dissolving protein deposits in the brain
Tauopathien sind neurodegenerative Erkrankungen, bei denen sich sogenannte Tau-Proteine im Gehirn ansammeln. Das Tau-Protein ist ein wichtiges Strukturprotein, das Nervenzellen stabilisiert. Bei neurodegenerativen Krankheiten wie Alzheimer und fronto-temporaler Demenz bilden sich veränderte Formen des Tau-Proteins, die als hyperphos-phoryliertes Tau-Protein bezeichnet werden. Es verliert seine Funktion und Ablagerungen sammeln sich an. In Zusammenarbeit mit der Forschungsgruppe von Prof. Dr. Myöhänen, Universität Helsinki, stellten Dr. Elena Puris und Dr. Mikko Gynther fest, dass im Tiermodell durch die Hemmung eines bestimmten Enzyms die durch diese Ablagerungen bedingten Krankheitssymptome verringert und normale kognitiven Fähigkeiten wiederhergestellt werden können.
26. – 28.5.2025
BARRIER- AND TRANSPORTER-DAYS, BAD HERRENALB
Die Arbeitsgruppe von Prof. Fricker veranstaltet zum 24. Mal die „Barrier- and Transporter-Days“ in Bad Herrenalb bei Karlsruhe. 92 Experten aus Hochschule und Industrie treffen sich, um 2 Tage lang aktuelle Themen der Wirkstoffverabreichung, des Drug Targetings und der Modellsysteme zum Wirkstofftransport zu diskutieren.
11.5.2023
SUCCESS IN THE HEI-INNOVATION COMPETITION AT THE UNIVERSITY OF HEIDELBERG
Junior Prof. Dr. Philipp Uhl and his team "Rovance" (Florian Umstätter, Julia Werner, Eric Mühlberg, Tyra Christian and Walter Mier) won the first prize of 5,000 euros in the "Science and Tech Innovations" category for the development of a platform technology to overcome antibiotic resistance.
21.4.2023
Workshop „PK principles in drug delivery“
Under the direction of Dr. Elena Puris and Dr. Mikko Gynther, the Department of Technology and Biopharmacy ...
14.12.2022
BMBF Förderung in Höhe von 1.089.595 Euro
The team led by JunProf. Dr. Uhl has received funding of €1,089,595.15 as part of the VIP+-funded joint project "ROVANCE" - Chemical modification of established antibiotics using peptide conjugation to overcome the resistance problem. The aim of the "ROVANCE" project is to reactivate established antibiotics.
1.12.2022
SUCCESSFUL IN THE EU
Prof. Fricker's group is a member of the new EURAS consortium with 10 international partners, which aims to research pathophysiological principles and translate these findings into therapies for RASopathies. The consortium is funded with 8.5 million euros by the EU program "HORIZON-HLTH-2022- Development of new effective therapies for rare diseases".
23.11.2022
Funding from the Alzheimer Research Initiative e.V. for Dr. Elena Puris
Dr. Elena Puris receives a research grant of 50,000 euros from the Alzheimer Research Initiative e.V. (AFI) for her project "The roles of transporters in amyloid-ß brain clearance in Alzheimer Disease".
01.10.2022
New junior professorship for Dr. Philipp Uhl
Dr. rer. nat. Philipp Uhl has accepted the call to the W1 junior professorship for "Pharmaceutical Technology with a focus on phospholipids (Lipoid Endowed Professorship)" and has been strengthening the team of the Department of Pharmaceutical Technology and Biopharmacy at the IPMB since 1.10.2022.
20.3.2022
Funding by the Phospholipid Research Center Heidelberg
For their project "Stabilization of Lyso-Phosphatidylcholine-levels in patients with cancer", Prof. Fricker and Prof. Massing (University of Freiburg) received funding from the Phospholipid Research Center in the amount of €135,600.
07.02.2022
Klaus-Georg and Sigrid Hengstberger Prize 2021 for Dr. Elena Puris
Dr. Elena Puris has been awarded the Klaus-Georg and Sigrid Hengstberger Prize 2021 for young scientists at Heidelberg University, which is endowed with 15,000 euros. She is using the prize money to organize a symposium on 2 and 3 April on the topic of "Brain barriers in CNS diseases: New therapeutic strategies and approaches to drug delivery".
